
CLAIMS

1. Use of a compound of formula **I**



(**I**),

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a neuropathic pain in a subject in need thereof, wherein the medicament is for administration of the compound of formula (**I**), or a pharmaceutically acceptable salt thereof at a dosage of either 200 mg two times per day (BID) or 250 mg three times per day (TID), wherein the neuropathic pain is diabetic neuropathy or trigeminal neuralgia.

2. The use of claim 1, wherein the compound of formula **I** is in the form of a hydrochloride salt.


3. The use of claim 1, wherein the medicament is for administration of the compound of formula **I**, or a pharmaceutically acceptable salt thereof at a dosage of 200 mg two times per day (BID).

4. The use of claim 1, wherein the medicament is for administration of the compound of formula **I**, or a pharmaceutically acceptable salt thereof at a dosage of 250 mg three times per day (TID).

5. The use of claim 4, wherein the 250 mg TID dosage is for administration to a subject not previously treated with the compound of formula **I**, or a pharmaceutically acceptable salt thereof.

6. The use of claim 4, wherein the 250 mg TID dosage is for administration to a subject previously treated with a 150 mg dosage of the compound of formula **I**, or a pharmaceutically acceptable salt thereof, wherein the subject has been identified as a non-responder to treatment with the 150 mg dosage of the compound of formula **I**, or a pharmaceutically acceptable salt thereof.

7. Use of a compound of formula **I**



(**I**),

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a neuropathic pain in a subject in need thereof, wherein the medicament is for administration of the compound of formula (**I**), or a pharmaceutically acceptable salt thereof at a dosage of either 300 mg or 400 mg two times per day (BID), and the neuropathic pain is diabetic neuropathy or trigeminal neuralgia.

8. The use of claim 7, wherein the compound of formula **I** is in the form of a hydrochloride salt.

9. The use of claim 7, wherein the 300 mg BID dosage is for administration to a female subject.

10. The use of claim 7, wherein the 300 mg BID dosage is for administration following a dosage of 400 mg BID for an initial period of time.

11. The use of claim 10, wherein the initial period of time is approximately 1 week.

12. The use of claim 10, wherein the 400 mg BID dosage is for administration to a male subject.


13. The use of any one of claims 1 to 12, wherein the medicament is for oral administration.

14. The use of any one of claims 1 to 12, wherein the medicament is for administration in combination with one or more therapeutically effective medicaments.

15. The use of claim 1, wherein the neuropathic pain is trigeminal neuralgia (TN) and the compound of formula **I**, or a pharmaceutically acceptable salt thereof, is for administration to a subject in need thereof at a dosage of 250 mg three times per day (TID).

16. The use of any one of claims 1 to 15, wherein the medicament is a pharmaceutical composition comprising one or more pharmaceutically acceptable carrier(s), diluent(s) and/or excipient(s).

17. Use of a compound of formula **I**



(**I**),


or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or condition mediated by modulation of Nav1.7 in a subject in need thereof, wherein the medicament is for administration after the subject is instructed to stop using a UGT inducer.

18. The use of claim 17, wherein the UGT inducer is selected from rifampin, ritonavir, ethinyl estradiol, methsuximide, phenytoin, phenobarbital, rifabutin, carbamazepine and oxcarbazepine.

19. The use of claim 18, wherein the UGT inducer is carbamazepine.

20. The use of any one of claims 17-19, wherein the medicament is for administration at least three weeks after the subject is instructed to stop using the UGT inducer.

21. Use of a compound of formula **I**



(**I**)

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or condition mediated by modulation of Nav1.7 in a subject in need thereof, wherein the subject is using a UGT inducer.

22. The use of claim 21, wherein the UGT inducer is selected from rifampin, ritonavir, ethinyl estradiol, methsuximide, phenytoin, phenobarbital, rifabutin, carbamazepine and oxcarbazepine.

23. The use of claim 22, wherein the UGT inducer is carbamazepine.

24. The use of any one of claims 21-23, wherein the medicament is for administration of the compound of formula (**I**), or a pharmaceutically acceptable salt thereof at a dosage which is at least 30% higher relative to what it would have been had the subject not been using carbemazepine.

25. The use of claim 24, wherein the medicament is for administration of the compound of formula (**I**), or a pharmaceutically acceptable salt thereof at a dosage which is at least 50% higher relative to what it would have been had the subject not been using carbemazepine.

26. The use of claim 25, wherein the medicament is for administration of the compound of formula (**I**), or a pharmaceutically acceptable salt thereof at a dosage which is increased to250 mg three times per day (TID).